Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Effect of aspirin on all-cause mortality in the healthy elderly

    Access Status
    Fulltext not available
    Authors
    McNeil, J.
    Nelson, M.
    Woods, R.
    Lockery, J.
    Wolfe, R.
    Reid, Christopher
    Kirpach, B.
    Shah, R.
    Ives, D.
    Storey, E.
    Ryan, J.
    Tonkin, A.
    Newman, A.
    Williamson, J.
    Margolis, K.
    Ernst, M.
    Abhayaratna, W.
    Stocks, N.
    Fitzgerald, S.
    Orchard, S.
    Trevaks, R.
    Beilin, L.
    Donnan, G.
    Gibbs, P.
    Johnston, C.
    Radziszewska, B.
    Grimm, R.
    Murray, A.
    Date
    2018
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    McNeil, J. and Nelson, M. and Woods, R. and Lockery, J. and Wolfe, R. and Reid, C. and Kirpach, B. et al. 2018. Effect of aspirin on all-cause mortality in the healthy elderly. New England Journal of Medicine. 379 (16): pp. 1519-1528.
    Source Title
    New England Journal of Medicine
    DOI
    10.1056/NEJMoa1803955
    ISSN
    0028-4793
    School
    School of Public Health
    URI
    http://hdl.handle.net/20.500.11937/74680
    Collection
    • Curtin Research Publications
    Abstract

    Background: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo. Methods: From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or =65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. Deaths were classified according to the underlying cause by adjudicators who were unaware of trial-group assignments. Hazard ratios were calculated to compare mortality between the aspirin group and the placebo group, and post hoc exploratory analyses of specific causes of death were performed. Results: Of the 19,114 persons who were enrolled, 9525 were assigned to receive aspirin and 9589 to receive placebo. A total of 1052 deaths occurred during a median of 4.7 years of follow-up. The risk of death from any cause was 12.7 events per 1000 person-years in the aspirin group and 11.1 events per 1000 person-years in the placebo group (hazard ratio, 1.14; 95% confidence interval [CI], 1.01 to 1.29). Cancer was the major contributor to the higher mortality in the aspirin group, accounting for 1.6 excess deaths per 1000 person-years. Cancer-related death occurred in 3.1% of the participants in the aspirin group and in 2.3% of those in the placebo group (hazard ratio, 1.31; 95% CI, 1.10 to 1.56). Conclusions: Higher all-cause mortality was observed among apparently healthy older adults who received daily aspirin than among those who received placebo and was attributed primarily to cancer-related death. In the context of previous studies, this result was unexpected and should be interpreted with caution.

    Related items

    Showing items related by title, author, creator and subject.

    • Effect of aspirin on disability-free survival in the healthy elderly
      McNeil, J.; Woods, R.; Nelson, M.; Reid, Christopher; Kirpach, B.; Wolfe, R.; Storey, E.; Shah, R.; Lockery, J.; Tonkin, A.; Newman, A.; Williamson, J.; Margolis, K.; Ernst, M.; Abhayaratna, W.; Stocks, N.; Fitzgerald, S.; Orchard, S.; Trevaks, R.; Beilin, L.; Donnan, G.; Gibbs, P.; Johnston, C.; Ryan, J.; Radziszewska, B.; Grimm, R.; Murray, A. (2018)
      Background: Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disabilityfree life in healthy seniors ...
    • Effect of aspirin on cardiovascular events and bleeding in the healthy elderly
      McNeil, J.; Wolfe, R.; Woods, R.; Tonkin, A.; Donnan, G.; Nelson, M.; Reid, Christopher; Lockery, J.; Kirpach, B.; Storey, E.; Shah, R.; Williamson, J.; Margolis, K.; Ernst, M.; Abhayaratna, W.; Stocks, N.; Fitzgerald, S.; Orchard, S.; Trevaks, R.; Beilin, L.; Johnston, C.; Ryan, J.; Radziszewska, B.; Jelinek, M.; Malik, M.; Eaton, C.; Brauer, D.; Cloud, G.; Wood, E.; Mahady, S.; Satterfield, S.; Grimm, R.; Murray, A. (2018)
      Background: Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who ...
    • Effect of aspirin on cancer incidence and mortality in older adults.
      McNeil, John J; Gibbs, Peter; Orchard, Suzanne G; Lockery, Jessica E; Bernstein, Wendy B; Cao, Yin; Ford, Leslie; Haydon, Andrew; Kirpach, Brenda; Macrae, Finlay; McLean, Catriona; Millar, Jeremy; Murray, Anne M; Nelson, Mark R; Polekhina, Galina; Reid, Christopher ; Richmond, Ellen; Rodríguez, Luz Maria; Shah, Raj C; Tie, Jeanne; Umar, Asad; van Londen, G.J.; Ronaldson, Kathlyn; Wolfe, Rory; Woods, Robyn L; Zalcberg, John; Chan, Andrew T; ASPREE Investigator Group (2020)
      BACKGROUND: ASPirin in Reducing Events in the Elderly (ASPREE), a randomized double-blind placebo-controlled trial (RCT) of daily low-dose aspirin (100 mg) in older adults, showed an increase in all-cause mortality, ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.